A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

This study is for adults aged 18 or older. To be considered for Part 1 of the study, you must have advanced small cell lung cancer, a specific type of advanced large cell neuroendocrine lung cancer, or certain advanced neuroendocrine cancers that have spread to other parts of the body. Your doctor will confirm if your cancer type fits these descriptions, especially if your tumour is made up of different cell types.

You should have already tried other available treatments that haven't worked or are not suitable for you, and these treatments must usually include a chemotherapy called platinum-based chemotherapy, unless there's a good medical reason you couldn't have it.

For Part 2 of the study, it's specifically for people with advanced small cell lung cancer (known as 'extended stage'). You must not have had any previous treatment for this type of advanced small cell lung cancer. However, if you had chemoradiotherapy for a less advanced stage of the disease, you might still be eligible if it was at least six months ago.

If you join the study, you will receive the study medicines as infusions directly into a vein. In Part 1, you will get obrixtamig and ZL-1310. In Part 2, you will receive obrixtamig, ZL-1310, and an additional medicine called a checkpoint inhibitor (atezolizumab). All participants in Part 2 must have advanced small cell lung cancer.

There isn't a set time limit for how long you'll be in the study. You can continue to receive treatment for up to two years, as long as the treatment is helping you and you are tolerating it well. You will need to visit the study clinic regularly, and some of these visits might involve staying overnight. During these visits, the study team will closely monitor your health for any side effects from the treatment, check the size of your tumours, and take blood samples for lab tests.